Nightingale Health published new disease risk assessments

Translation: Original published in Finnish on 1/24/2025 at 08:28 am EET

Nightingale announced that it has published two new disease risk assessments for its Health Check service: fatty liver disease and stroke. The company’s service now covers seven types of disease risk assessments with a single blood sample that have at least the same performance (Area Under the Curve, AUC)  as the current methods. At the same time, Nightingale facilitates the integration of any routine clinical workflows into risk measurement and announced that it will publish a country- and ethnic-adjusted risk assessment in Singapore (already completed) and the US (to be finalized in the first quarter of 2025).

Nightingale constantly seeks to expand and refine its risk assessments based on blood analysis, so the release is not surprising. Each release improves the coverage of the service and makes it a more useful tool for healthcare. The company already has commercial partners in Singapore (Innoquest Diagnostics) and the US (Boston Heart), the latter having several growth starts in different stages with numerous other partners. We believe the bottleneck in Nightingale’s business growth is not the extent of the solution or the ability to enter into partnerships, but rather the time it takes to carry out pilots and studies with partners. So, the release does not affect our view of the company. The next checkpoint in the company's investment story is the H2'24 report, which, according to the current schedule, will be published on March 6, 2025.